Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures

What impact will Trump's trade deal with Britain have? Why did Google stock drop after Apple search remarks? How is Netflix's new homepage redesign significant? What risks are Fed officials warning about amid tariffs? Why is Ford raising prices on Mexico-made vehicles? How are US-China trade talks affecting markets? What caused disruptions at Newark Liberty International Airport? Why is WeightWatchers filing for bankruptcy now? How will ending Energy Star affect consumers?

Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures

benzinga.com/tech/25/05/45246495/cathie-wood-backed-tempus-ai-says-pharma-contracts-solid-despite-biotech-funding-challenges-tariff-pressures

Tempus AI Inc. (NASDAQ:TEM), a key holding in Cathie Wood's Ark Invest portfolio, reassured investors Tuesday that its major pharmaceutical contracts remain strong despite challenges in biotech funding and global tariff concerns.
What Happened: During the company's first-quarter earnings…

This story appeared on benzinga.com, 2025-05-07 09:37:52.